• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

Comprehensive Overview of 1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol (CAS No. 1114523-54-4)

1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol (CAS No. 1114523-54-4) is a specialized organic compound widely utilized in pharmaceutical and agrochemical research. This brominated fluoropyridine derivative is recognized for its unique structural properties, making it a valuable intermediate in the synthesis of bioactive molecules. With the growing demand for heterocyclic compounds in drug discovery, this chemical has garnered significant attention from researchers and industry professionals alike.

The compound's molecular structure features a pyridine ring substituted with both bromine and fluorine atoms, alongside a hydroxyl-bearing ethyl group. This configuration enhances its reactivity, enabling diverse applications in cross-coupling reactions and catalyzed transformations. Recent studies highlight its role in developing kinase inhibitors and antiviral agents, aligning with the current focus on targeted therapies and infectious disease research.

In the context of green chemistry trends, 1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol is often discussed for its potential in sustainable synthesis routes. Researchers are exploring microwave-assisted reactions and flow chemistry techniques to optimize its production efficiency while minimizing environmental impact. These innovations address the rising demand for eco-friendly chemical processes—a top priority for modern pharmaceutical manufacturers.

Analytical characterization of this compound typically involves advanced techniques such as NMR spectroscopy, HPLC-MS, and X-ray crystallography. Its stability under various conditions makes it suitable for high-throughput screening applications, particularly in fragment-based drug design. The 2-bromo-5-fluoropyridine moiety is particularly noteworthy for its ability to participate in palladium-catalyzed couplings, a feature frequently leveraged in medicinal chemistry pipelines.

From a commercial perspective, CAS 1114523-54-4 is increasingly listed in catalogs of fine chemical suppliers, reflecting its expanding industrial relevance. Quality control protocols emphasize ≥98% purity standards, with strict adherence to ICH guidelines for impurities profiling. The compound's shelf life and storage recommendations (typically 2-8°C under inert atmosphere) are critical considerations for end-users.

Emerging applications include its use as a building block for PET radiotracers in diagnostic imaging, capitalizing on the fluorine-19 nucleus for MRI contrast enhancement. This aligns with the booming theranostics market, where multifunctional compounds bridge diagnostic and therapeutic capabilities. Such interdisciplinary applications demonstrate the compound's versatility beyond traditional synthetic roles.

Safety assessments indicate standard handling precautions for organic intermediates, with particular attention to moisture-sensitive characteristics. While not classified as hazardous under GHS criteria, proper laboratory PPE (gloves, goggles) is recommended during manipulation. These protocols mirror broader industry shifts toward enhanced occupational safety standards in chemical research facilities.

The synthesis of 1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol typically proceeds through regioselective bromination of fluoropyridine precursors, followed by Grignard addition to introduce the ethanol moiety. Process chemists are actively refining these routes to improve atom economy and reduce heavy metal residues—key metrics in contemporary process optimization strategies.

Patent literature reveals growing intellectual property activity surrounding derivatives of 4-substituted pyridines, with 1114523-54-4 frequently appearing in claims for cancer therapeutics and CNS drugs. This correlates with market analytics showing increased R&D investment in precision oncology and neurodegenerative disease treatments—sectors where pyridine scaffolds show particular promise.

For analytical scientists, the compound presents interesting chromatographic behavior due to its polar-nonpolar duality, requiring specialized UHPLC methods for accurate quantification. This characteristic has prompted method development studies published in separation science journals, contributing to broader discussions on HPLC column selection for halogenated heterocycles.

In educational contexts, 1-(2-Bromo-5-fluoropyridin-4-yl)ethan-1-ol serves as an excellent case study for retrosynthetic analysis in advanced organic chemistry courses. Its straightforward yet instructive transformation pathways help students master functional group interconversions and protecting group strategies—fundamental skills for aspiring synthetic chemists.

The compound's commercial availability through custom synthesis providers has increased accessibility for academic labs, accelerating structure-activity relationship studies. This democratization of specialized chemicals supports the global open innovation movement in life sciences research, where collaborative discovery models are gaining traction.

Looking forward, the demand for halogenated pyridine derivatives like 1114523-54-4 is projected to grow in parallel with advancements in bioconjugation techniques and proteolysis-targeting chimeras (PROTACs). These cutting-edge modalities frequently incorporate similar structural motifs, ensuring the compound's continued relevance in next-generation drug discovery paradigms.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)